The Impact of Uremic Toxicity Induced Inflammatory Response on the Cardiovascular Burden in Chronic Kidney Disease

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Immunology

Background:

• Uremic toxin (UT) accumulation in chronic kidney disease (CKD) is linked to adverse health outcomes.
• Cardiovascular disease (CVD) is a major cause of mortality in CKD patients.
• The interplay between UT, inflammation, and cardiovascular response biomarkers in CKD requires further elucidation.

Purpose of the Study:

• To investigate the associations between UT, inflammatory biomarkers, and biomarkers of the uremic cardiovascular response (BUCVR) in CKD patients.
• To assess the impact of these biomarkers on cardiovascular status.
• To identify predictors of mortality in CKD patients.

Main Methods:

• Cross-sectional study of 67 CKD patients (stages 3-5) measuring UT (IS, pCS, IAA), inflammatory markers (IL-6, hsCRP, MCP-1, sVCAM-1, sICAM-1, sFas), and BUCVRs (sCD36, sRAGE, fractalkine).
• Longitudinal follow-up for 5.2 years with all-cause mortality as the primary outcome.
• Immunohistochemistry analysis of artery segments from a separate cohort of CKD patients.

Main Results:

• Strong interrelations were observed between estimated glomerular filtration rate (eGFR), circulating UT, inflammatory biomarkers, and BUCVRs.
• CKD patients with arterial plaque showed increased UT-induced inflammation and higher fractalkine receptor (CX3CR1) expression in arteries.
• Circulating indoxyl sulfate (IS), p-cresil sulfate (pCS), IL-6, sFas, sCD36, and fractalkine independently predicted total mortality risk.

Conclusions:

• Uremic toxicity plays a significant role in the pathogenesis of CVD in CKD patients, primarily through inflammatory pathways.
• Specific UTs and inflammatory biomarkers are crucial predictors of mortality in CKD.
• Understanding these pathways can inform strategies to mitigate cardiovascular risk in CKD.